Therapies and Protocols Library
Every article, presentation, spotlight, and news item we've tagged to Therapies and Protocols.
Showing 49–72 of 79
Abinopharm releases AbinoNutra® NMN white paper after FDA reinstatement and clinical evidence
Abinopharm released a white paper on AbinoNutra® NMN following FDA regulatory clarification confirming NMN's legality as a dietary supplement ingredient. A randomized, double-blind clinical trial demonstrated that 60 days of NMN supplementation at doses up to 900 mg increased blood NAD⁺ levels, improved physical performance and endurance, and showed favorable shifts in biological age markers with no serious adverse events.
At-home EEG sleep detection matches clinical-grade accuracy
Beacon Biosignals demonstrated machine learning-based detection of sleep arousals using a 510(k) FDA-cleared at-home EEG headband, with performance metrics comparable to expert clinical assessment. This capability addresses a critical measurement gap in sleep phenotyping for both clinical trials and population health assessment, particularly in populations taking antidepressants where sleep disruption is both common and therapeutically relevant.
Home EEG tracking enables frequent Alzheimer's measurement
A year-long home-based study of 119 participants demonstrates that individuals with mild Alzheimer's disease can reliably self-administer frequent brain health assessments using a wireless EEG headset and cognitive task platform, achieving 99.7% completion rates and generating high-frequency data that may accelerate clinical trial design and reduce costs.
Direct-to-Brain Stem Cells Reduce Tau in Alzheimer's
Regeneration Biomedical's direct-to-brain stem cell therapy received FDA Fast Track designation for Alzheimer's disease, following Phase 1 data showing safety, reductions in phosphorylated tau, and improved amyloid PET measures. This represents a shift toward regenerative approaches that address neurodegeneration at the cellular level rather than symptomatic management alone.
Neural Regeneration Outpaces Dopamine Replacement in Parkinson's
TreeFrog Therapeutics' TFG-001, a 3D neural microtissue therapy, demonstrated accelerated dopamine release and neural reconnection in preclinical Parkinson's models, suggesting a shift from symptomatic treatment toward regenerative restoration of damaged neural architecture. This approach addresses a fundamental longevity challenge: whether neurodegenerative decline can be reversed through structural repair rather than chemical compensation.
Circadian Light Therapy Restores Sleep and Cognition in Mild Impairment
A randomized controlled trial found that home-based light therapy tailored to individual circadian timing improved sleep quality, mood, and cognitive performance in people with mild cognitive impairment. Light exposure calibrated to circadian phase represents a practical intervention accessible outside clinical settings.
Science Corp and Neurosoft unite to speed brain-computer care
A partnership between Science Corporation and Neurosoft Bioelectronics reduces brain-computer interface development costs from $75–100 million to under $5 million, accelerating clinical adoption of therapies for neurological conditions including epilepsy and tinnitus. For longevity practitioners, this infrastructure advancement enables faster restoration of neurological function and cognitive independence—essential dimensions of healthspan that outlive lifespan alone.
Epia Neuro debuts with stroke-focused BCI
Epia Neuro has launched an implantable brain-computer interface designed to help stroke survivors translate neural intent into functional movement through assistive devices. The approach prioritizes practical restoration of independence in daily life rather than speculative enhancement, addressing a significant gap in post-stroke rehabilitation where functional disability persists across years or decades.
A Single Sauna Session Causes White Blood Cell Mobilization
A single 30-minute sauna session at 73°C triggers a transient increase in circulating white blood cells, with neutrophils and lymphocytes rising immediately post-session and returning to baseline within 30 minutes. This mobilization effect suggests a mechanism through which regular sauna use may confer documented cardiovascular and longevity benefits.
NB4168 bioavailability edge for rare disease clinical trials
Niagen Bioscience is advancing NB4168, an oral candidate for Ataxia Telangiectasia, through preclinical development with contract partner Evotec. Nonclinical studies show NB4168 achieves substantially higher blood exposure than NR chloride, positioning the compound for IND submission and clinical evaluation.
Menopausal Hormone Therapy Does Not Increase Mortality
An analysis of over 800,000 Danish women found no association between menopausal hormone therapy and increased all-cause mortality over 7-21 years of follow-up. This challenges the prevailing safety concerns that emerged from earlier studies and suggests the risk-benefit calculation for hormone therapy in perimenopausal women warrants reassessment based on individual clinical context.
Cognito Therapeutics presents Spectris data in Alzheimer’s disease
Cognito Therapeutics presented clinical and biomarker data supporting Spectris, a non-invasive neurostimulation therapy using synchronized light and sound to modulate gamma frequency brain waves in Alzheimer's disease. Prior studies showed preserved brain structure, slowed cognitive decline, and reduced atrophy compared with controls, with favorable safety profiles and no amyloid-related imaging abnormalities.
Cognision launches cognision360 platform for CNS trial biomarkers
Cognision360 consolidates neurobiomarker data collection and analysis for CNS clinical trials through automated workflows and standardized integration of EEG, sleep, eye tracking, wearables, and cognitive assessments. The platform addresses fragmentation in multi-site studies and accelerates regulatory pathways by improving data integrity and reducing manual processing errors.
Cells that heal? New Parkinson’s trial sparks hope
A Phase II clinical trial of XS411, a stem cell therapy designed to replace dopamine-producing neurons lost in Parkinson's disease, has advanced based on encouraging Phase I results showing improved motor function and no adverse events. The approach represents a shift from symptomatic management toward cellular repair, potentially restoring function rather than merely masking decline.
The first personalized brain repair for Parkinson’s
Aspen Neuroscience's autologous cell therapy for Parkinson's disease demonstrates early restoration of motor function and quality of life through transplantation of patient-derived dopamine-producing neurons into the brain. This represents a shift from symptomatic management toward biological reconstruction of damaged neural tissue.
Selective NMDA Antagonism Preserves Neural Function in Neurodegeneration
Lys Therapeutics secured €25 million to advance LYS241, a monoclonal antibody targeting pathological interactions between tissue plasminogen activator and NMDA receptors. The approach addresses blood-brain barrier dysfunction and neuroinflammation in Parkinson's disease and ischemic stroke by preserving normal receptor function while blocking disease-driving signaling.
Beacon Biosignals upsizes Series B to more than $97 million
Beacon Biosignals raised $97 million in Series B extension funding to advance at-home EEG technology and AI-driven neural analytics for diagnostic and clinical applications. The capital supports commercialization of FDA-cleared wearable technology that captures real-world brain activity data for precision medicine.
AI-Accelerated Drug Discovery Narrows Path to Therapeutic Innovation
Insilico Medicine is advancing AI-driven pharmaceutical research through foundation models and specialized scientific agents designed to accelerate drug discovery. This represents a shift toward automated systems that could compress development timelines and expand the chemical and biological space available for therapeutic intervention.
Dynamin‐Related Protein 1‐Dependent Disruption of Mitochondrial Homeostasis Drives Blue Light‐Induced Epithelial‐Mesenchymal Transition in Retinal Aging
Blue light exposure triggers excessive mitochondrial fragmentation in retinal cells through a specific protein (Drp1), driving cellular changes associated with age-related macular degeneration. Blocking this fragmentation restores mitochondrial function and reverses the pathological transformation in both cell cultures and animal models.
RNA therapies research lists 80+ companies, 100+ drugs
A comprehensive market analysis catalogs over 80 RNA therapy companies and 100+ drug candidates across multiple modalities—mRNA, siRNA, antisense oligonucleotides, aptamers, and CRISPR approaches. The research examines development stages, delivery mechanisms, and commercial landscapes, with established players like Novartis and Arrowhead Pharmaceuticals advancing candidates across multiple therapeutic areas.
Voyager pushes IV gene therapy for Alzheimer’s
Voyager Therapeutics has demonstrated that engineered gene therapies can reach the brain via intravenous infusion rather than invasive delivery, with preclinical data showing VY1706 achieved safe, predictable distribution to the central nervous system in non-human primates. This addresses a fundamental bottleneck in neurological drug development and positions tau-silencing approaches as candidates for clinical translation in Alzheimer's disease.
Cortechs.ai partners with Siemens Healthineers to expand NeuroQuant access
Cortechs.ai and Siemens Healthineers have partnered to integrate NeuroQuant, an FDA-cleared AI neuroimaging tool, into clinical workflows for automated brain lesion tracking and volumetric quantification. This expands clinician access to objective, longitudinal brain imaging data for monitoring neurological disease progression and treatment response, including anti-amyloid therapies for Alzheimer's disease.
Insilico, Tenacia expand AI-driven CNS collaboration
Insilico Medicine and Tenacia Biotechnology are expanding their AI-driven collaboration to design small-molecule therapies for central nervous system disorders, with a focus on blood-brain barrier penetration. This partnership demonstrates how generative AI can accelerate drug discovery for neurological conditions, including a candidate targeting NLRP3 inflammation that has cleared FDA review for Parkinson's disease trials.
A Single Sauna Session Causes White Blood Cell Mobilization
A 30-minute sauna session at 73°C triggers acute mobilization of circulating white blood cells across all major subtypes—neutrophils, lymphocytes, and monocytes—without selective recruitment of specific immune populations. This transient spike in immune surveillance capacity may represent a physiological mechanism underlying the epidemiological associations between regular sauna use and reduced cardiovascular disease, stroke, dementia, and all-cause mortality risk.